Untargeted Metabolomics for Dietary Intervention Insights
Dietary intervention studies have historically relied on a limited panel of predefined endpoints: glucose and lipid profiles, inflammatory markers, anthropometric measurements, and questionnaire-based assessments. While these traditional biomarkers provide valuable...
Saving PRMT5 Drug Development with Metabolomics
How Metabolomic Biomarkers Could Save PRMT5 Drug Development The PRMT5 inhibitor field represents one of the most expensive lessons in modern oncology drug development. Despite massive investments – including Bristol Myers Squibb’s $4.8 billion acquisition...
Metabolic Signatures Reveal Molecular Glue Activity
Linking Protein Degradation to Functional Metabolic Consequences Molecular glue degraders induce targeted protein degradation through E3 ligase modulation, but measuring protein loss alone provides an incomplete picture of therapeutic activity. The functional...
Predict Responders in mRNA Trials via Metabolomics
Biomarker-Driven mRNA Trials: How Discovery Metabolomics Finds the Responders Before Treatment Your Phase 2 mRNA therapeutic trial enrolled sixty patients. Twenty showed remarkable responses. Thirty had modest benefits. Ten showed no response at all. Now you’re...